Abstract 1738P
Background
Tobacco remains the leading preventable risk factor for cancer in the world. Although the prevalence of tobacco use has a decreasing trend in most European countries, the availability of new smoking devices is causing an increase in smokers, especially among the younger population. Several studies have confirmed the relationship between this increase and indirect or covert advertising, carried out on social media and VOD platforms, through product placement, etc. This study aims to measure the impact of tobacco and new smoking devices in these digital spaces on the young Spanish population; and how this impact is related to increased consumption.
Methods
A survey has been conducted on the young Spanish population (aged between 16 to 21 years old) using a representative online panel of this population. The final sample obtained was 1730 interviews, and the data collection was conducted in December 2022. A questionnaire with an average duration of 10 minutes was administered, in which questions related to tobacco and new smoking devices use, and the recall of having seen content related to traditional tobacco and new smoking devices were collected. Descriptive and logistic regression analyses have been performed, taking the habitual consumption (last month) of tobacco and new smoking device as dependent variables.
Results
82.5% of young people remember having had some impact related to traditional tobacco, and 83% with new smoking forms. Among young people who have had this impact, there are twice as many smokers (53.1%) as among those who have not (24.5%). Having seen someone smoking cigarettes on these platforms (AOR 1.56), cigarette product placement (AOR 1.71), or recalling e-cigarette brands (AOR 1.58) are the variables that most increase the risk of regularly consuming traditional cigarettes. The same happens in the risk of habitual consumption of new devices, with the recall of having seen specific brands or logos taking special relevance (AOR 2.47).
Conclusions
There is a correlation between the recall of these types of consumption and the regular consumption of tobacco or new forms of smoking. It is necessary to continue researching this avenue of normalization of consumption and to ensure the protection of young people from the promotion of new devices.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Asociación Española Contra el Cáncer.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1912TiP - STELLAR-304: A randomized phase III study of zanzalintinib (XL092) and nivolumab in non-clear cell renal cell carcinoma (nccRCC)
Presenter: Sumanta Pal
Session: Poster session 23
2366P - Phase I-II study of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial)
Presenter: Daniel Castellano Gauna
Session: Poster session 23
2367P - A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Russells Pachynski
Session: Poster session 23
2368P - Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
Presenter: Patrizia Giannatempo
Session: Poster session 23
2369P - Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH)
Presenter: Bradley McGregor
Session: Poster session 23
2370P - Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Achille Bottiglieri
Session: Poster session 23
2371P - Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)
Presenter: Shilpa Gupta
Session: Poster session 23
2372P - Efficacy of a tailored approach with nivolumab (N) and nivolumab+ipilimumab (N+I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC
Presenter: Marc-Oliver Grimm
Session: Poster session 23
2373P - Outcomes by retrospective eligibility for maintenance therapy of patients (pts) with advanced urothelial carcinoma (UC): Post hoc analysis of KEYNOTE-361
Presenter: Ronac Mamtani
Session: Poster session 23
2374P - A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
Presenter: Petros Grivas
Session: Poster session 23